Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing.
Götte
Matthias
M
Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada. matthias.gotte@mcgill.ca
D024921:Drug Resistance, Multiple, Viral / Q000235:genetics*; D005820:Genetic Testing; D005838:Genotype; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D006801:Humans; D009154:Mutation; D019829:Nevirapine / Q000627:therapeutic use; D018579:Patient Selection; D010641:Phenotype; D017434:Protein Structure, Tertiary; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use
D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D019829:Nevirapine; C514824:reverse transcriptase, Human immunodeficiency virus 1; D054303:HIV Reverse Transcriptase